Date: 2017-06-19
Type of information: Research agreement
Compound: Antibody Targeted Amanitin Conjugates (ATACs)
Company: Takeda Pharmaceutical (Japan) Heidelberg Pharma (Germany)
Therapeutic area: undisclosed
Type agreement: research
Action mechanism: antibody drug conjugate
Disease:
Details:
- • On June 19, 2017, Wilex announced that its subsidiary, Heidelberg Pharma has signed an exclusive multi-target research agreement with Takeda Pharmaceutical for the joint development of antibody drug conjugates (ADCs) that use Amanitin as the payload.
- Under the terms of the exclusive multi-target research agreement, Heidelberg Pharma will produce Antibody Targeted Amanitin Conjugates (ATACs) using antibodies from Takeda’s proprietary portfolio for up to three undisclosed targets. Takeda has an option for an exclusive license for global development and commercialization rights to each of the product candidates resulting from the research collaboration. If it exercises the option, Takeda would be responsible for further preclinical and clinical development, as well as potential commercialization, of any product candidate it licenses. Takeda signed the agreement with Heidelberg Pharma through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.
Financial terms:
- Heidelberg Pharma will receive an upfront technology access fee and payments for research services. In the event Takeda exercises its option for an exclusive license, Heidelberg Pharma would receive an option fee. Under the exclusive license agreement, Heidelberg Pharma would be eligible to receive clinical development, regulatory and sales-related milestone payments of up to $ 113 million for each product candidate, as well as royalties. The expected financial impact of this partnership is already reflected in WILEX’s financial outlook for the current fiscal year provided in March 2017.
Latest news:
Is general: Yes
